Please assess the completion status of the following clinical trial:

Trial Title: Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with relapsed or refractory adult T-cell leukemia/lymphoma (ATL) who have history of treatment with mogamulizumab or are mogamulizumab intolerant, contraindication after treatment with at least 1 medication regimen~* Aged ≥20 years or older at the time of signing the informed consent~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2~* At least 1 evaluable lesion~* Participants who have defined laboratory criteria~* Life expectancy ≥ 3 months~Exclusion Criteria:~* A presence of central nervous system involvement at the time of screening tests~* Have poorly controlled complication (eg. chronic congestive heart failure, unstable angina~* ≥ Grade 3 neuropathy~* QT interval corrected using Fridericia's method (QTcF) \>470 ms~* Has an uncontrolled infection~* Participants who use corticosteroids over 10 mg/day~* Receipt of allogeneic hematopoietic stem cell transplantation~* History of, or concurrent, malignant tumors

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-3201b (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).